Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
Filed with ASX · · 5 pages · English
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Reinstatement to Official Quotation
- Breakthrough results with NTI164 in paediatric ASD
- Extension to Voluntary Suspension
- Suspension from Official Quotation
- Preclinical Success with Targeted Combination Therapies
Later from Neurotech International
- Executive Change
- New Phase I/II Clinical Trial in Children with PANDAS/PANS
- 20 Week Data Shows Significant Improvement For ASD Children
- Neurotech Completes $9.0M Placement
- Reinstatement to Quotation
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International